Mavrilimumab
Based on 1 Customer Validation
Mavrilimumab (CAM 3001) is a monoclonal antibody that binds to the α subunit of the granulocyte-macrophage colony stimulating factor (GM-CSF) receptor and blocks intracellular signalling downstream of GM-CSF. GM-CSF might be a mediator of the hyperactive inflammatory response associated with respiratory failure and death.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 98.37%
- CAS. Nr.: 1085337-57-0
- Molecular Weight:143.168 kDa
-
Speicherung:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
Beschreibung
Isotype
Human IgG4 lambda
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
CSF2Ra/GM-CSFRa/CD116
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Cynomolgus monkey models[2]
-
Dosage:3-100 mg/kg
-
Administration:iv, once a week for at least 11 weeks
-
Result:Produced foam cells in the lungs.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG4 lambda2
Anwendung
ELISA, FACS, Functional assay
Verified Bioactivity
-
Loaded Mavrilimumab on AHC2 biosensor, can bind GM-CSF R alpha Protein, Human (HEK293, His, HY-P7783) with an affinity constant of 7.867E-10 M as determined in BLI assay. -
Flow Cytometry analysis of Hela cells labelling GM-CSFRa (red) with Mavrilimumab (anti-GM-CSFRa) (HY-P99031). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG4 (S228P) lambda1(HY-P99987). Black-Unlabelled control, cells without incubation with primary antibody.
Chemical Information
-
CAS. Nr. 1085337-57-0
-
Appearance Liquid
-
Molecular Weight 143.168 kDa
-
Color Colorless to light yellow
-
SMILES
[Mavrilimumab]
-
Synonyms
CAM 3001
-
Versand
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
-
Data Sheet (259 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Verweise
[1]. Paul C Cremer, et al. Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial. Lancet Rheumatol. 2021 Jun;3(6):e410-e41 [Content Brief]
[2]. Ryan PC, et al., Nonclinical safety of mavrilimumab, an anti-GMCSF receptor alpha monoclonal antibody, in cynomolgus monkeys: relevance for human safety. Toxicol Appl Pharmacol. 2014 Sep 1;279(2):230-9. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)